array(40) {
  [0]=>
  string(4) "2040"
  ["article_id"]=>
  string(4) "2040"
  [1]=>
  string(166) "New Study Demonstrates Safety and Effectiveness of the MiniMed(TM) 640G System Reducing Hypoglycemia Compared with Insulin Pump Therapy Without CGM in Type 1 Diabetes"
  ["article_title"]=>
  string(166) "New Study Demonstrates Safety and Effectiveness of the MiniMed(TM) 640G System Reducing Hypoglycemia Compared with Insulin Pump Therapy Without CGM in Type 1 Diabetes"
  [2]=>
  string(3) "   "
  ["short_description"]=>
  string(3) "   "
  [3]=>
  string(10) "
   
"
  ["description"]=>
  string(10) "
   
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "25"
  ["rss_id"]=>
  string(2) "25"
  [14]=>
  string(236) "http://www.globenewswire.com/news-release/2019/05/09/1819929/0/en/New-Study-Demonstrates-Safety-and-Effectiveness-of-the-MiniMed-TM-640G-System-Reducing-Hypoglycemia-Compared-with-Insulin-Pump-Therapy-Without-CGM-in-Type-1-Diabetes.html"
  ["blog_url"]=>
  string(236) "http://www.globenewswire.com/news-release/2019/05/09/1819929/0/en/New-Study-Demonstrates-Safety-and-Effectiveness-of-the-MiniMed-TM-640G-System-Reducing-Hypoglycemia-Compared-with-Insulin-Pump-Therapy-Without-CGM-in-Type-1-Diabetes.html"
  [15]=>
  string(19) "2019-05-09 12:59:00"
  ["add_date"]=>
  string(19) "2019-05-09 12:59:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:41:08"
  ["create_at"]=>
  string(19) "2019-05-09 16:41:08"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "2493"
  ["article_id"]=>
  string(4) "2493"
  [1]=>
  string(56) "BioCryst Completes Phase 1 Clinical Trial of Galidesivir"
  ["article_title"]=>
  string(56) "BioCryst Completes Phase 1 Clinical Trial of Galidesivir"
  [2]=>
  string(150) "RESEARCH TRIANGLE PARK, N.C., May 09, 2019 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced the completion of a random"
  ["short_description"]=>
  string(150) "RESEARCH TRIANGLE PARK, N.C., May 09, 2019 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced the completion of a random"
  [3]=>
  string(252) "RESEARCH TRIANGLE PARK, N.C., May 09, 2019 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced the completion of a randomized, placebo-controlled Phase 1 clinical trial to evaluate intravenous (IV) galidesivir in healthy..."
  ["description"]=>
  string(252) "RESEARCH TRIANGLE PARK, N.C., May 09, 2019 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced the completion of a randomized, placebo-controlled Phase 1 clinical trial to evaluate intravenous (IV) galidesivir in healthy..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "15"
  ["rss_id"]=>
  string(2) "15"
  [14]=>
  string(202) "https://www.drugs.com/clinical_trials/biocryst-completes-phase-1-clinical-trial-galidesivir-18143.html?utm_source=ddc&utm_medium=rss&utm_campaign=BioCryst+Completes+Phase+1+Clinical+Trial+of+Galidesivir"
  ["blog_url"]=>
  string(202) "https://www.drugs.com/clinical_trials/biocryst-completes-phase-1-clinical-trial-galidesivir-18143.html?utm_source=ddc&utm_medium=rss&utm_campaign=BioCryst+Completes+Phase+1+Clinical+Trial+of+Galidesivir"
  [15]=>
  string(19) "2019-05-09 09:05:54"
  ["add_date"]=>
  string(19) "2019-05-09 09:05:54"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-23 14:18:34"
  ["create_at"]=>
  string(19) "2019-05-23 14:18:34"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "2041"
  ["article_id"]=>
  string(4) "2041"
  [1]=>
  string(136) "Quorum Health Corporation Selects R1 RCM for End-to-End Revenue Cycle Management Across 26 Hospitals and Outpatient Centers in 14 States"
  ["article_title"]=>
  string(136) "Quorum Health Corporation Selects R1 RCM for End-to-End Revenue Cycle Management Across 26 Hospitals and Outpatient Centers in 14 States"
  [2]=>
  string(150) "CHICAGO, May  08, 2019  (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ:RCM), a leading provider of technology-enabled revenue cycle management (RCM) services"
  ["short_description"]=>
  string(150) "CHICAGO, May  08, 2019  (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ:RCM), a leading provider of technology-enabled revenue cycle management (RCM) services"
  [3]=>
  string(440) "
CHICAGO, May  08, 2019  (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ:RCM), a leading provider of technology-enabled revenue cycle management (RCM) services to healthcare providers, announced today that a wholly owned subsidiary of Quorum Health Corporation has selected R1 RCM to provide end-to-end revenue cycle management services across Quorum Health’s portfolio of hospitals and outpatient centers. 
"
  ["description"]=>
  string(440) "
CHICAGO, May  08, 2019  (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ:RCM), a leading provider of technology-enabled revenue cycle management (RCM) services to healthcare providers, announced today that a wholly owned subsidiary of Quorum Health Corporation has selected R1 RCM to provide end-to-end revenue cycle management services across Quorum Health’s portfolio of hospitals and outpatient centers. 
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "25"
  ["rss_id"]=>
  string(2) "25"
  [14]=>
  string(207) "http://www.globenewswire.com/news-release/2019/05/09/1819902/0/en/Quorum-Health-Corporation-Selects-R1-RCM-for-End-to-End-Revenue-Cycle-Management-Across-26-Hospitals-and-Outpatient-Centers-in-14-States.html"
  ["blog_url"]=>
  string(207) "http://www.globenewswire.com/news-release/2019/05/09/1819902/0/en/Quorum-Health-Corporation-Selects-R1-RCM-for-End-to-End-Revenue-Cycle-Management-Across-26-Hospitals-and-Outpatient-Centers-in-14-States.html"
  [15]=>
  string(19) "2019-05-09 09:00:00"
  ["add_date"]=>
  string(19) "2019-05-09 09:00:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:41:08"
  ["create_at"]=>
  string(19) "2019-05-09 16:41:08"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "2042"
  ["article_id"]=>
  string(4) "2042"
  [1]=>
  string(69) "NextCure Announces Pricing of Initial Public Offering of Common Stock"
  ["article_title"]=>
  string(69) "NextCure Announces Pricing of Initial Public Offering of Common Stock"
  [2]=>
  string(150) "BELTSVILLE, Md., May  08, 2019  (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering"
  ["short_description"]=>
  string(150) "BELTSVILLE, Md., May  08, 2019  (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering"
  [3]=>
  string(1097) "
BELTSVILLE, Md., May  08, 2019  (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the pricing of its initial public offering of 5,000,000 shares of its common stock at a public offering price of $15.00 per share. NextCure also granted the underwriters a 30-day option to purchase up to an additional 750,000 shares of its common stock. NextCure’s common stock has been approved for listing and is expected to begin trading on The Nasdaq Global Select Market on May 9, 2019 under the ticker symbol “NXTC”. Gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, will be $75.0 million, excluding any exercise of the underwriters' option to purchase additional shares. The offering is expected to close on or about May 13, 2019, subject to the satisfaction of customary closing conditions.
"
  ["description"]=>
  string(1097) "
BELTSVILLE, Md., May  08, 2019  (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the pricing of its initial public offering of 5,000,000 shares of its common stock at a public offering price of $15.00 per share. NextCure also granted the underwriters a 30-day option to purchase up to an additional 750,000 shares of its common stock. NextCure’s common stock has been approved for listing and is expected to begin trading on The Nasdaq Global Select Market on May 9, 2019 under the ticker symbol “NXTC”. Gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, will be $75.0 million, excluding any exercise of the underwriters' option to purchase additional shares. The offering is expected to close on or about May 13, 2019, subject to the satisfaction of customary closing conditions.
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "25"
  ["rss_id"]=>
  string(2) "25"
  [14]=>
  string(140) "http://www.globenewswire.com/news-release/2019/05/09/1819899/0/en/NextCure-Announces-Pricing-of-Initial-Public-Offering-of-Common-Stock.html"
  ["blog_url"]=>
  string(140) "http://www.globenewswire.com/news-release/2019/05/09/1819899/0/en/NextCure-Announces-Pricing-of-Initial-Public-Offering-of-Common-Stock.html"
  [15]=>
  string(19) "2019-05-09 08:46:00"
  ["add_date"]=>
  string(19) "2019-05-09 08:46:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:41:08"
  ["create_at"]=>
  string(19) "2019-05-09 16:41:08"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "2043"
  ["article_id"]=>
  string(4) "2043"
  [1]=>
  string(59) "Axcella Health Announces Pricing of Initial Public Offering"
  ["article_title"]=>
  string(59) "Axcella Health Announces Pricing of Initial Public Offering"
  [2]=>
  string(150) "CAMBRIDGE, Mass., May  08, 2019  (GLOBE NEWSWIRE) -- Axcella Health Inc., a biotechnology company pioneering the research and development of novel mul"
  ["short_description"]=>
  string(150) "CAMBRIDGE, Mass., May  08, 2019  (GLOBE NEWSWIRE) -- Axcella Health Inc., a biotechnology company pioneering the research and development of novel mul"
  [3]=>
  string(1279) "
CAMBRIDGE, Mass., May  08, 2019  (GLOBE NEWSWIRE) -- Axcella Health Inc., a biotechnology company pioneering the research and development of novel multifactorial interventions to address dysregulated metabolism and support health, today announced the pricing of its initial public offering of 3,571,428 shares of common stock at a public offering price of $20.00 per share, before underwriting discounts and commissions.  In addition, Axcella has granted the underwriters a 30-day option to purchase up to an additional 535,714 shares of common stock at the initial public offering price, less the underwriting discounts and commissions.  Axcella’s common stock is expected to begin trading on The Nasdaq Global Market on May 9, 2019, under the ticker symbol “AXLA.”  All of the common stock in the offering is being offered by Axcella.  The gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Axcella, are expected to be $71.4 million, excluding any exercise of the underwriters’ option to purchase additional shares.  The offering is expected to close on May 13, 2019, subject to the satisfaction of customary closing conditions.
"
  ["description"]=>
  string(1279) "
CAMBRIDGE, Mass., May  08, 2019  (GLOBE NEWSWIRE) -- Axcella Health Inc., a biotechnology company pioneering the research and development of novel multifactorial interventions to address dysregulated metabolism and support health, today announced the pricing of its initial public offering of 3,571,428 shares of common stock at a public offering price of $20.00 per share, before underwriting discounts and commissions.  In addition, Axcella has granted the underwriters a 30-day option to purchase up to an additional 535,714 shares of common stock at the initial public offering price, less the underwriting discounts and commissions.  Axcella’s common stock is expected to begin trading on The Nasdaq Global Market on May 9, 2019, under the ticker symbol “AXLA.”  All of the common stock in the offering is being offered by Axcella.  The gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Axcella, are expected to be $71.4 million, excluding any exercise of the underwriters’ option to purchase additional shares.  The offering is expected to close on May 13, 2019, subject to the satisfaction of customary closing conditions.
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "25"
  ["rss_id"]=>
  string(2) "25"
  [14]=>
  string(130) "http://www.globenewswire.com/news-release/2019/05/09/1819898/0/en/Axcella-Health-Announces-Pricing-of-Initial-Public-Offering.html"
  ["blog_url"]=>
  string(130) "http://www.globenewswire.com/news-release/2019/05/09/1819898/0/en/Axcella-Health-Announces-Pricing-of-Initial-Public-Offering.html"
  [15]=>
  string(19) "2019-05-09 08:40:00"
  ["add_date"]=>
  string(19) "2019-05-09 08:40:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:41:08"
  ["create_at"]=>
  string(19) "2019-05-09 16:41:08"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "2044"
  ["article_id"]=>
  string(4) "2044"
  [1]=>
  string(105) "Novartis to acquire Xiidra®, expanding front-of-eye portfolio and strengthening leadership in eye care"
  ["article_title"]=>
  string(105) "Novartis to acquire Xiidra®, expanding front-of-eye portfolio and strengthening leadership in eye care"
  [2]=>
  string(150) "Basel, May 9, 2019 - Novartis announced today that it has entered into an agreement with Takeda Pharmaceutical Company Limited to acquire the assets a"
  ["short_description"]=>
  string(150) "Basel, May 9, 2019 - Novartis announced today that it has entered into an agreement with Takeda Pharmaceutical Company Limited to acquire the assets a"
  [3]=>
  string(785) "
Basel, May 9, 2019 - Novartis announced today that it has entered into an agreement with Takeda Pharmaceutical Company Limited to acquire the assets associated with Xiidra® (lifitegrast ophthalmic solution) 5% worldwide. Xiidra is the first and only prescription treatment approved to treat both signs and symptoms of dry eye by inhibiting inflammation caused by the disease[2]. The transaction would bolster the Novartis front-of-the-eye portfolio and ophthalmic leadership. Closing of the transaction is expected in second half of 2019, subject to customary closing conditions including regulatory approvals. On closing, Novartis plans a smooth transition of operations and integration of Xiidra into its pharmaceuticals portfolio.
"
  ["description"]=>
  string(785) "
Basel, May 9, 2019 - Novartis announced today that it has entered into an agreement with Takeda Pharmaceutical Company Limited to acquire the assets associated with Xiidra® (lifitegrast ophthalmic solution) 5% worldwide. Xiidra is the first and only prescription treatment approved to treat both signs and symptoms of dry eye by inhibiting inflammation caused by the disease[2]. The transaction would bolster the Novartis front-of-the-eye portfolio and ophthalmic leadership. Closing of the transaction is expected in second half of 2019, subject to customary closing conditions including regulatory approvals. On closing, Novartis plans a smooth transition of operations and integration of Xiidra into its pharmaceuticals portfolio.
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "25"
  ["rss_id"]=>
  string(2) "25"
  [14]=>
  string(171) "http://www.globenewswire.com/news-release/2019/05/08/1819862/0/en/Novartis-to-acquire-Xiidra-expanding-front-of-eye-portfolio-and-strengthening-leadership-in-eye-care.html"
  ["blog_url"]=>
  string(171) "http://www.globenewswire.com/news-release/2019/05/08/1819862/0/en/Novartis-to-acquire-Xiidra-expanding-front-of-eye-portfolio-and-strengthening-leadership-in-eye-care.html"
  [15]=>
  string(19) "2019-05-09 06:20:00"
  ["add_date"]=>
  string(19) "2019-05-09 06:20:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:41:08"
  ["create_at"]=>
  string(19) "2019-05-09 16:41:08"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "2356"
  ["article_id"]=>
  string(4) "2356"
  [1]=>
  string(55) "Medical News Today: How do you prevent type 2 diabetes?"
  ["article_title"]=>
  string(55) "Medical News Today: How do you prevent type 2 diabetes?"
  [2]=>
  string(154) "Several factors increase a person's risk of developing type 2 diabetes. In this article, learn about how to prevent the condition by losing weight, ex"
  ["short_description"]=>
  string(154) "Several factors increase a person's risk of developing type 2 diabetes. In this article, learn about how to prevent the condition by losing weight, ex"
  [3]=>
  string(191) "Several factors increase a person's risk of developing type 2 diabetes. In this article, learn about how to prevent the condition by losing weight, exercising, and eating a balanced diet."
  ["description"]=>
  string(191) "Several factors increase a person's risk of developing type 2 diabetes. In this article, learn about how to prevent the condition by losing weight, exercising, and eating a balanced diet."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "97"
  ["rss_id"]=>
  string(2) "97"
  [14]=>
  string(52) "https://www.medicalnewstoday.com/articles/325130.php"
  ["blog_url"]=>
  string(52) "https://www.medicalnewstoday.com/articles/325130.php"
  [15]=>
  string(19) "2019-05-09 06:00:00"
  ["add_date"]=>
  string(19) "2019-05-09 06:00:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:42:18"
  ["create_at"]=>
  string(19) "2019-05-09 16:42:18"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "2020"
  ["article_id"]=>
  string(4) "2020"
  [1]=>
  string(44) "HHS to Pharma: TV Ads Must Show Us the Money"
  ["article_title"]=>
  string(44) "HHS to Pharma: TV Ads Must Show Us the Money"
  [2]=>
  string(158) "&#nl        PhRMA on Wednesday pushed back against a final rule that will require drugmakers to offer a treatment’s list price as part of television ad"
  ["short_description"]=>
  string(158) "&#nl        PhRMA on Wednesday pushed back against a final rule that will require drugmakers to offer a treatment’s list price as part of television ad"
  [3]=>
  string(230) "&#nl        PhRMA on Wednesday pushed back against a final rule that will require drugmakers to offer a treatment’s list price as part of television ads, hinting that a First Amendment lawsuit might be on its way.&#nl      "
  ["description"]=>
  string(230) "&#nl        PhRMA on Wednesday pushed back against a final rule that will require drugmakers to offer a treatment’s list price as part of television ads, hinting that a First Amendment lawsuit might be on its way.&#nl      "
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "16"
  ["rss_id"]=>
  string(2) "16"
  [14]=>
  string(83) "https://www.fdanews.com/articles/191233-hhs-to-pharma-tv-ads-must-show-us-the-money"
  ["blog_url"]=>
  string(83) "https://www.fdanews.com/articles/191233-hhs-to-pharma-tv-ads-must-show-us-the-money"
  [15]=>
  string(19) "2019-05-09 05:23:00"
  ["add_date"]=>
  string(19) "2019-05-09 05:23:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:35:57"
  ["create_at"]=>
  string(19) "2019-05-09 16:35:57"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "2357"
  ["article_id"]=>
  string(4) "2357"
  [1]=>
  string(71) "Medical News Today: Everything you need to know about fecal transplants"
  ["article_title"]=>
  string(71) "Medical News Today: Everything you need to know about fecal transplants"
  [2]=>
  string(150) "Fecal transplants are a recent development in the treatment of several conditions, including Clostridium difficile infections. Learn more about this t"
  ["short_description"]=>
  string(150) "Fecal transplants are a recent development in the treatment of several conditions, including Clostridium difficile infections. Learn more about this t"
  [3]=>
  string(196) "Fecal transplants are a recent development in the treatment of several conditions, including Clostridium difficile infections. Learn more about this treatment and the emerging research on it here."
  ["description"]=>
  string(196) "Fecal transplants are a recent development in the treatment of several conditions, including Clostridium difficile infections. Learn more about this treatment and the emerging research on it here."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "97"
  ["rss_id"]=>
  string(2) "97"
  [14]=>
  string(52) "https://www.medicalnewstoday.com/articles/325128.php"
  ["blog_url"]=>
  string(52) "https://www.medicalnewstoday.com/articles/325128.php"
  [15]=>
  string(19) "2019-05-09 05:00:00"
  ["add_date"]=>
  string(19) "2019-05-09 05:00:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:42:18"
  ["create_at"]=>
  string(19) "2019-05-09 16:42:18"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "2045"
  ["article_id"]=>
  string(4) "2045"
  [1]=>
  string(88) "Media Statement from Amedisys Commending the  Home Health Payment Innovation Act of 2019"
  ["article_title"]=>
  string(88) "Media Statement from Amedisys Commending the  Home Health Payment Innovation Act of 2019"
  [2]=>
  string(155) "BATON ROUGE, La., May  08, 2019  (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), America’s leading independent home health, hospice and personal "
  ["short_description"]=>
  string(155) "BATON ROUGE, La., May  08, 2019  (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), America’s leading independent home health, hospice and personal "
  [3]=>
  string(298) "
BATON ROUGE, La., May  08, 2019  (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), America’s leading independent home health, hospice and personal care company, commends bipartisan legislation to preserve and expand home health to those who need it the most.
"
  ["description"]=>
  string(298) "
BATON ROUGE, La., May  08, 2019  (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), America’s leading independent home health, hospice and personal care company, commends bipartisan legislation to preserve and expand home health to those who need it the most.
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "26"
  ["rss_id"]=>
  string(2) "26"
  [14]=>
  string(158) "http://www.globenewswire.com/news-release/2019/05/08/1819810/0/en/Media-Statement-from-Amedisys-Commending-the-Home-Health-Payment-Innovation-Act-of-2019.html"
  ["blog_url"]=>
  string(158) "http://www.globenewswire.com/news-release/2019/05/08/1819810/0/en/Media-Statement-from-Amedisys-Commending-the-Home-Health-Payment-Innovation-Act-of-2019.html"
  [15]=>
  string(19) "2019-05-09 04:49:00"
  ["add_date"]=>
  string(19) "2019-05-09 04:49:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:41:16"
  ["create_at"]=>
  string(19) "2019-05-09 16:41:16"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "2066"
  ["article_id"]=>
  string(4) "2066"
  [1]=>
  string(74) "Wireless movement-tracking system could collect health and behavioral data"
  ["article_title"]=>
  string(74) "Wireless movement-tracking system could collect health and behavioral data"
  [2]=>
  string(150) "We live in a world of wireless signals flowing around us and bouncing off our bodies. Researchers are now leveraging those signal reflections to provi"
  ["short_description"]=>
  string(150) "We live in a world of wireless signals flowing around us and bouncing off our bodies. Researchers are now leveraging those signal reflections to provi"
  [3]=>
  string(241) "We live in a world of wireless signals flowing around us and bouncing off our bodies. Researchers are now leveraging those signal reflections to provide scientists and caregivers with valuable insights into people's behavior and health. "
  ["description"]=>
  string(241) "We live in a world of wireless signals flowing around us and bouncing off our bodies. Researchers are now leveraging those signal reflections to provide scientists and caregivers with valuable insights into people's behavior and health. "
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "29"
  ["rss_id"]=>
  string(2) "29"
  [14]=>
  string(62) "https://www.sciencedaily.com/releases/2019/05/190508164643.htm"
  ["blog_url"]=>
  string(62) "https://www.sciencedaily.com/releases/2019/05/190508164643.htm"
  [15]=>
  string(19) "2019-05-09 04:46:43"
  ["add_date"]=>
  string(19) "2019-05-09 04:46:43"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:41:23"
  ["create_at"]=>
  string(19) "2019-05-09 16:41:23"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "2046"
  ["article_id"]=>
  string(4) "2046"
  [1]=>
  string(56) "Dr. Eric Culbertson Enters 2019 with a New Certification"
  ["article_title"]=>
  string(56) "Dr. Eric Culbertson Enters 2019 with a New Certification"
  [2]=>
  string(150) "The San Francisco-based plastic surgeon at The Jacobs Center for Cosmetic Surgery in the San Francisco Bay Area is now officially certified by the Ame"
  ["short_description"]=>
  string(150) "The San Francisco-based plastic surgeon at The Jacobs Center for Cosmetic Surgery in the San Francisco Bay Area is now officially certified by the Ame"
  [3]=>
  string(372) "The San Francisco-based plastic surgeon at The Jacobs Center for Cosmetic Surgery in the San Francisco Bay Area is now officially certified by the American Board of Plastic Surgery 
The San Francisco-based plastic surgeon at The Jacobs Center for Cosmetic Surgery in the San Francisco Bay Area is now officially certified by the American Board of Plastic Surgery
"
  ["description"]=>
  string(372) "The San Francisco-based plastic surgeon at The Jacobs Center for Cosmetic Surgery in the San Francisco Bay Area is now officially certified by the American Board of Plastic Surgery 
The San Francisco-based plastic surgeon at The Jacobs Center for Cosmetic Surgery in the San Francisco Bay Area is now officially certified by the American Board of Plastic Surgery
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "26"
  ["rss_id"]=>
  string(2) "26"
  [14]=>
  string(126) "http://www.globenewswire.com/news-release/2019/05/08/1819802/0/en/Dr-Eric-Culbertson-Enters-2019-with-a-New-Certification.html"
  ["blog_url"]=>
  string(126) "http://www.globenewswire.com/news-release/2019/05/08/1819802/0/en/Dr-Eric-Culbertson-Enters-2019-with-a-New-Certification.html"
  [15]=>
  string(19) "2019-05-09 04:43:00"
  ["add_date"]=>
  string(19) "2019-05-09 04:43:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:41:16"
  ["create_at"]=>
  string(19) "2019-05-09 16:41:16"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}